Zobrazeno 1 - 10
of 84
pro vyhledávání: '"J. Pippen"'
Autor:
C Stokoe, Svetislava J. Vukelja, Scot Sedlacek, Stephen E. Jones, JE Schwartz, Hartmut Koeppen, J. Pippen, Joanne L. Blum, Kristi McIntyre, R. J. Brooks, R Rivera, Timothy R. Wilson, Jill M. Spoerke, L Krekow, M Crockett, Devchand Paul, Frankie A. Holmes, DL Lindquist, Maren K. Levin, Mark R. Lackner, Joyce A. O'Shaughnessy
Publikováno v:
Cancer Research. 73:P6-09
Background: USON 01062 (O’Shaughnessy J, et al. Proc SABCS, 2010, abst S4-2) showed no improvement in the primary endpoint of disease-free survival (DFS) (median FU 5 yrs: HR 0.84, 95% CI: 0.67-1.05; p = 0.125) with the addition of capecitabine (X)
Autor:
Joyce A. O'Shaughnessy, Gerald Edelman, J. Pippen, Alicia Clawson, Michael Savin, Nicholas J. Robert, Joanne L. Blum, Robert Kirby, Brian V. Geister
Publikováno v:
Clinical Breast Cancer. 7:850-856
Purpose Nanoparticle albumin-bound paclitaxel, a solvent-free, albumin-bound paclitaxel, demonstrated antitumor activity in patients with taxane-naive metastatic breast cancer (MBC). We examined albumin-bound paclitaxel (100 mg/m2 or 125 mg/m2 admini
Autor:
J. Pippen, David Dodwell
Publikováno v:
Clinical Breast Cancer. 7:244-247
Background: The different pharmacokinetic profiles of the intramuscularly administered antioestrogen fulvestrant and oral endocrine treatments have led to speculation among some physicians that this could result in a delayed time to response (TTR) wi
Autor:
CK Osborne, C. Morris, M. Ellis, J.T. May, J. Pippen, A. Buzdar, S.E. Jones, Gary V. Burton, A. Webster, Steven E. Come, Richard M. Elledge, Stan Gertler, I. Dimery, Leroy M. Parker
Publikováno v:
Journal of Clinical Oncology. 20:3386-3395
PURPOSE: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) with anastrozole in the treatment of advanced breast cancer in patients whose disease progresses on prior endocrine treatment. PATIENTS AND METHODS: In this doubl
Publikováno v:
Breast cancer research and treatment. 130(3)
Every-2-week (dose-dense) adjuvant doxorubicin (A) plus cyclophosphamide (C) followed by cremophor-formulated paclitaxel (cf-P) was efficacious in metastatic breast cancer (BC). Albumin-bound paclitaxel (ab-P) was safe and more effective than cf-P, a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J. Pippen, Thomas Marsland, Suresh Ratnam, Gary Kimmel, Joyce A. O'Shaughnessy, Sasha Vukelja
Publikováno v:
Clinical breast cancer. 5(2)
We evaluated the efficacy and toxicity of trastuzumab plus gemcitabine in patients with HER2-positive metastatic breast cancer (MBC). Sixty-four patients were enrolled, the majority of whom (95%) had been treated with an anthracycline and a taxane be
Autor:
Joanne L. Blum, F. Gilberg, Devchand Paul, R Rivera, R.E. Pluenneke, C Brownstein, R. J. Brooks, JE Schwartz, Kristi McIntyre, L Krekow, Stephen E. Jones, Frankie A. Holmes, DL Lindquist, Joyce A. O'Shaughnessy, C Stokoe, J. Pippen, Svetislava J. Vukelja, Scot Sedlacek
Publikováno v:
Cancer Research. 70:S4-2
Background: Combination regimens incorporating anthracyclines and taxanes are among the most effective for EBC and are particularly suitable for pts with high-risk disease. Significant efficacy benefit has been shown in phase III trials integrating c
Publikováno v:
Cancer Research. 69:2134-2134
Background: HER2/neu (HER2) positive breast cancers are associated with worse survival, resistance to cyclophosphamide/methotrexate/fluorouracil, and hypothesized to be sensitive to anthracyclines. It has been postulated that only a subset of HER2 po